Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00744497 · ClinicalTrials.gov registry record · Phase 3
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,930
- Enrollment target
NCT00744497: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00744497 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,930 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (150% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00744497, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,930 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
Primary Outcome
Overall survival is defined as time in months from the randomization date to the date of death due to any cause (in the randomized population). If the patient did not die, survival was censored on the last date he or she was known to be alive.
Interventions
- DRUG Placebo
- DRUG Docetaxel
- DRUG Prednisone
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,930 participants |
| Start Date | 2008-10 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
What the finished NCT00744497 record still lists
NCT00744497 is an interventional study that assigns participants to a tested intervention. Its 1,930 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (150% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00744497 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00744497 about?
NCT00744497 is a clinical study titled "Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer". The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
What is the current status of trial NCT00744497?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,930 participants. The study started on 2008-10. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00744497?
The interventions under investigation include: Placebo (DRUG), Docetaxel (DRUG), Prednisone (DRUG), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00744497?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00744497's enrollment target sits among peer trials
1,930 109th of 2000 higher than 1,892 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT06799117 · 1,912 participants · NA
Adaptive Decision Support for Addiction Treatment Master
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia